Gan & Lee Pharmaceuticals said it has received a drug registration approval in Honduras for its insulin glargine injection in a prefilled pen format.
According to Jin10, the company announced that it recently obtained a registration certificate issued by Honduras' National Medicines Regulatory Authority for insulin glargine injection (prefilled pen), with approval number HN-BT-0426-0005.
The product name is VITAGLAR, with an indication for diabetes. The dosage form is an injectable, with a specification of 3 ml at 100 units/ml (prefilled pen).
The company cited Honduras data stating the country has a total population of about 10.82 million and GDP per capita of $3,426.4. It also cited estimates that in 2024, Honduras had about 259,000 people aged 20 to 79 with diabetes, a diabetes prevalence rate of 4.0%, an undiagnosed rate of 51.9%, and average annual diabetes-related spending per patient of $789.4.
Gan & Lee Pharmaceuticals Wins Honduras Drug Registration for Vitaglar Insulin Glargine Prefilled Pen
2026-07-09 09:07:40
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
